drugset / Trial / NCT01835782
Determining the Safety of L-serine in ALS
Phase 1/2
Unknown
20 enrolled
Phoenix Neurological Associates, LTD
Institute for Ethnomedicine · collab
RandomizedFactorialQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety of L-Serine in subjects with Amyotrophic Lateral Sclerosis (ALS) at varied doses.
Timeline
- Start
- 2013-01
- Primary completion
- 2016-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | L-serine | Other / unclassified | 0.5 g | — |
| Comparator | L-serine | Other / unclassified | 2.5 g | — |
| Comparator | L-serine | Other / unclassified | 7.5 g | — |
| Comparator | L-serine | Other / unclassified | 15 g | — |